Subscribe
istock-614844028_triloks-3-
16 November 2018Big Pharma

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

Supplementary protection certificates (SPCs) are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSPN Europe 2018: Russian litigation and US second medical use
20 November 2018   The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
Big Pharma
LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer
19 November 2018   The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.
Big Pharma
SPC waiver proposal could discourage innovation, says pharma group
9 August 2018   A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
LSPN Europe 2018: Russian litigation and US second medical use
20 November 2018   The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
Big Pharma
LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer
19 November 2018   The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.
Big Pharma
SPC waiver proposal could discourage innovation, says pharma group
9 August 2018   A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.

More on this story

Americas
LSPN Europe 2018: Russian litigation and US second medical use
20 November 2018   The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
Big Pharma
LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer
19 November 2018   The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.
Big Pharma
SPC waiver proposal could discourage innovation, says pharma group
9 August 2018   A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.

More features

Weight-loss clinic hits back at Novo Nordisk’s Ozempic TM allegations
Eisai and Merck shield blockbuster cancer drug from generic challenge
Fed Circ refuses to stay Novartis feud with MSN over Entresto
Moderna entities must face infringement suits, UPC rules
Baker McKenzie adds London partner with ‘enviable’ expertise
‘Keep calm and carry on’: UK+ regime stays post-Brexit
As AI shakes up pharma and biotech, can patent law keep up?
UK court clears the way for Amgen and Samsung to launch biosimilars